KeithFlahertyMD

PubMed

• Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C.
  Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz
  Clinical Cancer Research. 2024-10-22
• Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
  Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal
  Clinical Cancer Research. 2024-10-15
• Targeted Therapy Innovations for Melanoma.
  Dahiana Amarillo, Keith T Flaherty, Ryan J Sullivan
  Hematology/oncology Clinics of North America. 2024-10-01

Journal Articles

• Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor  
  Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
• Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
• A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow Melanoma  
  Keith T Flaherty, Jennifer A Wargo, Wiley
• Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
• When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age  
  Keith Flaherty, MD, Annals of Internal Medicine
• Join now to see all

Lectures

• Tissue Agnostic Drug Development Operational and Scientific Challenges. Tissue Agnostic Drug Development 
  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018